Navigation Links
Imagenetix, Inc. Reports Second Quarter and Six Month Results
Date:11/12/2008

- Second Quarter Revenue Increases by 45% From Prior Year

- Second Quarter After Tax Income of $199,000

- Six Month Revenue Increases by 37% From Prior Year

- Six Month After Tax Income of $786,000

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its second fiscal quarter and six month period ending September 30, 2008. Net sales for the quarter were $2,656,000 an increase of 45% from the $1,829,000 reported for the same period of the prior fiscal year and up 91% sequentially from revenue of $1,344,000 in the first fiscal 2009 quarter. For the six month period, net sales increased by 37% to $4,051,000 from $2,956,000 as was reported in the prior six month period.

After tax income for the second quarter increased to $199,000, $.02 per share, from the loss of ($631,000), ($.06) per share, during the same quarter of the prior fiscal year. For the six month period after tax income increased to $786,000, $.07 per share, compared to the loss of ($1,066,000), ($.10) per share, in the previous six month period. First quarter results included a one-time litigation settlement.

Commenting on the results for the quarter, Mr. William P. Spencer, Imagenetix's Chief Executive Officer said, "We have begun making progress in selling our Inflame Away-Celadrin(R) joint health formulas through mass market stores. We have advanced Celadrin through an in-store warehouse club test. Also, we have added distribution of Inflame Away-Celadrin through the #1 national supermarket retail chain this past quarter. With greater expansion and success in the supermarket and warehouse club segments of the mass market, our company would continue to see both increased revenues and improved gross profit margins which would translate into enhanced bottom line performance."

Imagenetix, based in San Diego, California, is an innovator of scientifically
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
3. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
4. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
5. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
6. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
7. BMP Sunstone Reports Third Quarter 2008 Financial Results
8. Endocare Reports Financial Results for Third Quarter 2008
9. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
10. Isis Reports Financial Results and Highlights for Third Quarter of 2008
11. OncoGenex Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Virginia (PRWEB) June 03, 2015 Photo-Eyewear™ ... changed its name to PogoTec™, Inc. ( http://www.PogoTec.com ... its electronic wearable device products and technologies it is ... creation of three business divisions, PogoTec™ will provide focused ... devices as follows: , , On-Track™ ...
(Date:6/3/2015)... GEA's Panther™ NS3006L is a ... fully-equipped laboratory unit that is designed for continuous operation ... plants. The Panther™ NS3006L achieves the same results as ... easy installation with simple operation, quick maintenance and is ... used in many different industries, such as food, dairy, ...
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ - Aptose ... clinical-stage company developing new therapeutics that target the underlying ... and Drug Administration (FDA) has granted the company orphan ... myeloid leukemia (AML). APTO-253, a first-in-class inducer of the ... a Phase Ib clinical trial in patients with AML, ...
(Date:6/2/2015)... , June 02, 2015 Research and ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3
... Conference Call and Webcast Today at 1:00 pm ... FRANCISCO, Calif., June 30 Anesiva,Inc. (Nasdaq: ... its first,commercial product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... that reduces the pain associated with peripheral,intravenous (IV) ...
... today,received information from Danske Bank, that the Danske Bank ... - through,acquisition today of 502,300 shares now owns 1,804,514 ... to 5,99% of the share capital and 5,99%,of the ... Exiqon,s corporate mission is to combine leading-edge scientific,expertise in ...
... with ADHD ages 6 to 65, RARITAN, N.J., ... and behavioral disorder treated in children(1), and,according to the ... 70 percent of children with ADHD continue to exhibit ... about eight million, or,one in 20, adults in the ...
Cached Biology Technology:Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 2Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 3Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 4Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 5FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 2FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 3FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults 4
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... the remote highlands of eastern Suriname discovered 24 species ... with florescent purple markings and other amphibians, fish and ... the findings from a 2005 expedition led by Conservation ... in 2006 demonstrate the value of exploring unknown regions ...
... so many people continue to suffer from life-altering, chronic pain ... answer -- and an effective treatment -- has long eluded ... haven’t worked very well. , A Northwestern University ... to be an old memory trace that essentially gets stuck ...
... cauliflower While orange cauliflower may seem unappealing to ... have identified the genetic mutation behind the unusual hue. ... including maize, potato, rice, sorghum and wheat. , ... Li Li and colleagues -- and described in the ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Old memory traces in brain may trigger chronic pain 2Old memory traces in brain may trigger chronic pain 3Discovery in orange cauliflower may lead to more nutritious crops 2
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Biology Products: